Tegafur-uracil
- Generic Name
- Tegafur-uracil
- Drug Type
- Small Molecule
- Chemical Formula
- C12H13FN4O5
- CAS Number
- 74578-38-4
- Unique Ingredient Identifier
- HMI5GR78FR
- Background
Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd. It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
- Indication
Tegafur-uracil is indicated for the first line treatment of metastatic colorectal cancer with concomitant administration of calcium folinate. Colorectal cancer is the third most diagnosed cancer and 30% of the cases can present the metastatic state.
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 68
- Registration Number
- NCT03121313
- Locations
- 🇨🇳
Chang-Gung Memorial Hospital-LinKou, Taoyuan City, Taiwan
The Maintenance Treatment of UFT in Advanced Gastric Cancer
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 58
- Registration Number
- NCT02903498
A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02887365
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2017-02-08
- Target Recruit Count
- 400
- Registration Number
- NCT02836977
- Locations
- 🇨🇳
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
- Conditions
- Vascular Endothelial Growth Factor OverexpressionAdult Hepatocellular CarcinomaRecurrent Hepatocellular CarcinomaAdverse Reaction to Drug
- Interventions
- Drug: thalidomine
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02447679
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan, Taiwan
Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 47
- Registration Number
- NCT01225744
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧North Wales Cancer Treatment Centre, Llansantffraid Glan Conwy, United Kingdom
🇬🇧The Royal Marsden, London and Surrey, United Kingdom
UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 115
- Registration Number
- NCT01037998
- Locations
- 🇨🇳
Taipei VGH, Taipei City, Taiwan
Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Target Recruit Count
- 1111
- Registration Number
- NCT00898846
- Locations
- 🇯🇵
Saitama Social Insurance Hospital, Saitama, Japan
🇯🇵Ban Buntane Houtokukai Hospital, Nagoya, Aichi, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Mackay Memorial Hospital
- Target Recruit Count
- 115
- Registration Number
- NCT00855881
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.